NASDAQ:CMRX - Chimerix Stock Price, Forecast & News

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix Inc (NASDAQ:CMRX) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.07. The biopharmaceutical company earned $1.96 million during the quarter, compared to the consensus estimate of $1.30 million. Chimerix had a negative net margin of 1,162.96% and a negative return on equity of 38.75%. View Chimerix's Earnings History.

Chimerix is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Chimerix.

Chimerix will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 brokers have issued 1 year price targets for Chimerix's stock. Their forecasts range from $2.00 to $7.00. On average, they expect Chimerix's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 131.2% from the stock's current price. View Analyst Price Targets for Chimerix.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

Media coverage about CMRX stock has trended positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chimerix earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Chimerix.

Chimerix saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 853,700 shares, a drop of 27.0% from the January 15th total of 1,170,000 shares. Based on an average daily trading volume, of 721,100 shares, the short-interest ratio is currently 1.2 days. Currently, 1.9% of the shares of the company are short sold. View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Calithera Biosciences (CALA), Dynavax Technologies (DVAX), Avid Bioservices (CDMO), Avedro (AVDR), DURECT (DRRX), Urovant Sciences (UROV), Mirum Pharmaceuticals (MIRM), Rigel Pharmaceuticals (RIGL), Galera Therapeutics (GRTX), Recro Pharma (REPH), Verrica Pharmaceuticals (VRCA), Lannett (LCI), Kindred Biosciences (KIN), Corbus Pharmaceuticals (CRBP) and Stemline Therapeutics (STML).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Wynn Resorts (WYNN), SLS International (SLS), Gilead Sciences (GILD), Walmart (WMT) and TherapeuticsMD (TXMD).

Chimerix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.81%), State Street Corp (1.99%), AQR Capital Management LLC (1.70%), Geode Capital Management LLC (1.45%), Acadian Asset Management LLC (1.38%) and UBS Group AG (0.95%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Garrett Nichols, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Institutional Ownership Trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Alambic Investment Management L.P., Goldman Sachs Group Inc., Bank of America Corp DE, Man Group plc and Rhumbline Advisers. View Insider Buying and Selling for Chimerix.

CMRX stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., Acadian Asset Management LLC, Ikarian Capital LLC, State Street Corp, Jacobs Levy Equity Management Inc. and AJO LP. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Insider Buying and Selling for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $1.73.

Chimerix has a market capitalization of $106.19 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.

The official website for Chimerix is http://www.chimerix.com/.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]